The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -14.31 — distress zone — historically elevated failure riskWatch
- Earnings-manipulation signal · Beneish M -21.81 — no flag raisedOK
- Earnings quality 62/100 — worth a closer lookWatch
Where the revenue comes from
Fiscal 2025, as Park Ha Biological Technology Co., Ltd. reports it. History and quarterly detail are in the app.
- Franchise Fees$1.5M
- Products Sales Nonfranchisees$536K
- Product Sales Franchisees$478K
Latest filings
- 6-K · Company announcement (foreign filer)2026-09-02
- 6-K · Company announcement (foreign filer)2026-08-03
- 6-K · Company announcement (foreign filer)2026-08-03
- 6-K · Company announcement (foreign filer)2026-07-24
- 6-K · Company announcement (foreign filer)2026-07-13
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Park Ha Biological Technology Co., Ltd., every answer cited to the official filings🔒
- The Intelligence Brief — added when Park Ha Biological Technology Co., Ltd.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.